If you’re starting a GLP-1 medicine, it’s completely normal to ask: Which one works the fastest?
The honest answer is you may feel appetite changes quickly, but meaningful weight loss is usually gradual, and ‘fastest’ depends a lot on dose escalation (titration), not just the drug name.
This blog explains what ‘fast’ really means, what research shows the leading GLP-1 options, and where Zydus’ oral GLP-1 (ZYOG1) fits in.
What does 'fast' mean with GLP-1s?
There are two different ‘speeds’ people experience:
- Fast appetite change (days to weeks): Many people notice reduced hunger and earlier fullness soon after starting, as GLP-1 medicines affect satiety and slow stomach emptying.
- Fast weight change (weeks to months): Actual fat loss takes time. Also, most GLP-1s start at a low dose and increase slowly to reduce side effects, so the first month is often a ‘getting used to it’ phase.
A practical benchmark from Mayo Clinic: clinicians often reassess whether a weight-loss medication is working after 3-6 months at the full dose (or the best-tolerated dose), aiming for meaningful progress like ~5% weight loss.
The Big factor: How Quickly the Dose Reaches an Effective Level
Because it reaches its target dose sooner, some people may see earlier scale movement, but average total weight loss tends to be more modest than newer agents.
Semaglutide (Wegovy) and tirzepatide (Zepbound/Mounjaro) ramp more slowly
- In STEP 1, semaglutide dose escalation progresses over multiple steps (e.g., 0.25 > 0.5 > 1.0 > 1.7 > 2.4 mg).
- Tirzepatide typically starts at 2.5 mg weekly for 4 weeks and increases every 4 weeks (2.5 mg increments) toward 10-15 mg.
So, while these newer weekly injections often deliver greater overall weight loss, they may not feel dramatically faster in month 1 because the dose is still ramping.
So… which one works fastest in real life?
Here’s a science-aligned way to think about it: Fastest early (first 4-8 weeks): often depends on titration + your body
- Liraglutide (Saxenda) reaches full dose by about week 5, which can help some people see earlier results.
- Semaglutide and tirzepatide may feel more gradual early on because you’re still titrating.
Fastest overall (after months, not weeks): tirzepatide and semaglutide lead
Mayo Clinic summarises that tirzepatide and semaglutide are among the most effective for weight loss overall.
Major trials back this up:
- Semaglutide 2.4 mg weekly (STEP 1) showed substantial average weight loss by week 68.
- Tirzepatide (SURMOUNT-1) showed very large average weight loss by week 72.
Bottom line:
- If you mean ‘fastest to meaningful, sustained weight loss,’ tirzepatide and semaglutide are strongest on published evidence.
- If you mean ‘fastest to reach full dose,’ liraglutide ramps earlier.
Where does ZYOG1 (Zydus oral GLP-1) fit in?
ZYOG1 is an oral (tablet) GLP-1 candidate developed by Zydus, and Zydus has described it as a next-generation option intended to avoid injections. What we can responsibly say today:
- Zydus has reported preclinical findings suggesting glucose/HbA1c reduction and an added benefit of weight loss, plus ‘no nausea-like symptoms’ in preclinical studies.
- Publicly accessible information does not provide robust, peer-reviewed Phase 3 human weight-loss outcomes that would allow a ‘fastest’ comparison versus Wegovy or tirzepatide.
Zydus is developing ZYOG1, an oral GLP-1 receptor agonist intended for type 2 diabetes and obesity. As further clinical data becomes available, it will help determine how its efficacy compares with currently approved injectable GLP-1 therapies.
Quick takeaways
- You may feel appetite reduction early, but scale changes usually build over weeks/months.
- Dose titration controls early speed: Saxenda reaches full dose sooner; Wegovy/tirzepatide ramps more slowly.
- For largest overall weight loss, evidence strongly supports tirzepatide and semaglutide.
- ZYOG1 is an oral GLP-1 candidate from Zydus with encouraging preclinical notes, but not yet comparable on ‘fastest weight loss in humans’.
If your goal is the fastest meaningful weight loss, the strongest published trial evidence points to tirzepatide and semaglutide over time. If your goal is a faster ramp to full dose, liraglutide (Saxenda) reaches maintenance dose earlier.
And looking ahead, Zydus’ ZYOG1 represents the direction the field is moving in: effective metabolic therapy in a more convenient oral form, pending stronger human trial data.
